Related Experiment Video

Updated: May 16, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K

Potential drug-drug interactions analysis in Polish pediatric hemato-oncologic unit, including acute lymphoblastic

Arkadiusz Adamiszak1,2, Julia Drobińska3, Izabela Niewiadomska-Wojnałowicz4

  • 1Department of Pharmacology, Poznan University of Medical Sciences, Rokietnicka 3, Poznań, 60-806, Poland. arkadiusz.adamiszak@student.ump.edu.pl.

Pharmacological Reports : PR
|April 1, 2025
PubMed

Insights

Pediatric drug-drug interactions are common, especially in hemato-oncology. Identifying risk factors like multiple medications and hospitalization length is crucial for improving patient safety and pharmacotherapy effectiveness.

Area of Science:

  • Pediatric Pharmacology
  • Clinical Pharmacy
  • Drug Safety

Background:

  • Limited data exists on drug-drug interactions (DDIs) in pediatric patients, complicating therapeutic decisions.
  • Pediatric hemato-oncology units, including those treating acute lymphoblastic leukemia (ALL), face unique challenges with potential DDIs.

Purpose of the Study:

  • To analyze the rate and risk factors of potential drug-drug interactions (pDDIs) in pediatric hemato-oncology patients.
  • To identify specific pDDIs in pediatric patients, with a focus on acute lymphoblastic leukemia (ALL) cases.

Main Methods:

  • A six-month prospective study involving clinical pharmacists reviewing medical records weekly.
  • Utilized Lexicomp® Drug Interactions Checker to identify pDDIs.
  • Employed statistical analyses including Spearman's rank coefficient, logistic regression, and U-Mann-Whitney test.

Main Results:

  • Identified 507 pDDIs in 119 patients; 388 were clinically relevant, with 68% experiencing significant interactions.
  • pDDIs positively correlated with the number of medications, off-label drug use, comorbidities, and hospitalization length.
  • Receiving ≥7 medications and ≥13 hospital days were identified as significant risk factors for pDDIs. ALL patients showed a higher incidence of pDDIs.

Conclusions:

  • The study highlights a significant prevalence of pDDIs in pediatric hemato-oncology patients.
  • Close collaboration between clinical pharmacists and clinicians is essential to enhance pharmacotherapy safety and effectiveness in this vulnerable population.
Abstract

Keywords:
Acute lymphoblastic leukemiaClinical pharmacyDrug-drug interactionsPediatric oncologyPediatrics

More Related Videos

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.1K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.0K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.7K
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
203
Factors Affecting Protein-Drug Binding: Drug Interactions01:23

Factors Affecting Protein-Drug Binding: Drug Interactions

Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
73